Annual General Meeting on April 29, 2021

GenSight Biologics successfully raises €30 million in an oversubscribed private placement with European and US institutional investors

GenSight Biologics launches a reserved offering of c. €25 million by means of an accelerated bookbuilding process

BioEurope Spring – virtual

GenSight Biologics Reports Full Year 2020 Financial Results and provides an Outlook on 2021

Cell & Gene Meeting on the Mediterranean, virtual

GenSight Biologics Reports Cash Position as of December 31, 2020 and Provides Operational Update

GenSight Biologics Announces its 2021 Financial Calendar

39th Annual J.P. Morgan Healthcare Conference – Virtual

GenSight Biologics announces the partial conversion of convertible bonds and full exercise of share warrants by Kreos Capital